Search

Displaying results 1621 - 1630 of 5392 in total
  1. Drug

    Light mineral oil

    go.drugbank.com/drugs/DB11579
    Approved

    Mixtures: Mineral Oil, Petrolatum, Phenylephrine Hydrochloride, Shark Liver Oil, QV FLARE UP BATH OILSynonyms: Mineral Oil Light, Mineral Oil, Light
  2. Drug

    Lactulose

    go.drugbank.com/drugs/DB00581
    ApprovedInvestigational

    patients diagnosed with PSE in a placebo study, the substance may just be one of many options available for treating constipation and its efficacy in managing PSE may never be formally confirmed or refuted via

    Synonyms: 4-O-beta-D-Galactopyranosyl-D-fructose, 4-O-beta-D-Galactopyranosyl-D-fructofuranoseProducts: BIFITERAL BEUTEL
  3. Drug

    Propantheline

    go.drugbank.com/drugs/DB00782
    Approved

    A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.

  4. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of...

  5. Drug

    Cyclacillin

    go.drugbank.com/drugs/DB01000
    Approved

    A cyclohexylamido analog of penicillanic acid.

  6. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion

  7. Drug

    Leflunomide

    go.drugbank.com/drugs/DB01097
    ApprovedInvestigational

    Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many othe...

    Products: Nu-leflunomide
  8. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (til...

  9. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.

    Categories: Dopamine D2 Receptor Antagonists
  10. Drug

    Oseltamivir

    go.drugbank.com/drugs/DB00198
    ApprovedInvestigational

    They recommend the use of oseltamivir in people with a higher risk of developing complications including children younger than 2 years, people over 65 years, people with some chronic conditions or immunosuppression … Notably, in 2017, the World Health Organization downgraded oseltamivir from its essential medicines list from a "core" drug to a "complementary" drug, due to limited cost-effectiveness.